Page 65 - 《南京医科大学学报（自然科学版）》2026年第3期

第46卷第3期 陶慧敏，徐嗣亮，侯 振. 女性恶性肿瘤患者生育力保存过程中来曲唑辅助卵巢刺激的研究现状
2026年3月 与展望［J］. 南京医科大学学报（自然科学版），2026，46（3）：366-374 ·373 ·

［21］BALKENENDE E M E，DAHHAN T，BEERENDONK C patients with endometrial cancer：a review of the litera⁃
C M，et al. Fertility preservation for women with breast⁃ ture［J］. J Clin Med，2021，10（20）：4784
cancer：a multicentre randomized controlled trial on vari⁃ ［32］LIN J，YANG T，LI L，et al. Analysis of assisted reproduc⁃
ous ovarian stimulation protocols［J］. Hum Reprod，2022， tive outcomes for gynecologic cancer survivors：a retro⁃
37（8）：1786-1794 spective study［J］. Reprod bio endocrinol，2024，22（1）：97
［22］ PEREIRA N，HANCOCK K，CORDEIRO C N，et al. Com⁃ ［33］ PARK J Y，SEONG S J，KIM T J，et al. Pregnancy out⁃
parison of ovarian stimulation response in patients with comes after fertility⁃sparing management in young women
breast cancer undergoing ovarian stimulation with letro⁃ with early endometrial cancer［J］. Obstet Gynecol，2013，
zole and gonadotropins to patients undergoing ovarian 121（1）：136-142
stimulation with gonadotropins alone for elective cryo⁃ ［34］CHEN J Y，CAO D Y，YANG J X，et al. Oncological and
preservation of oocytes［J］. Gynecol Endocrinol，2016，32 reproductive outcomes for gonadotropin⁃releasing hormone
（10）：823-826 agonist combined with aromatase inhibitors or levonorg⁃
［23］ SHULMAN Y，ALMOG B，KALMA Y，et al. Effects of estrel⁃releasing intra⁃uterine system in women with endo⁃
letrozole or tamoxifen coadministered with a standard metrial cancer or atypical endometrial hyperplasia［J］. Int
stimulation protocol on fertility preservation among breast J Gynecol Cancer，2022，32（12）：1561-1567
cancer patients［J］. J Assist Reprod Genet，2021，38（3）： ［35］ LI J H，LI M N，LI Y J，et al. Analysis of assisted repro⁃
743-750 ductive outcomes in patients with atypical endometrial
［24］AZIM A，OKTAY K. Letrozole for ovulation induction and hyperplasia and early ⁃ stage endometrial cancer after
fertility preservation by embryo cryopreservation in young fertility ⁃ sparing treatment［J］. Int J Gynaecol Obstet，
women with endometrial carcinoma［J］. Fertil Steril， 2025，168（2）：598-604
2007，88（3）：657-664 ［36］ ZHOU H M，CAO D Y，YANG J X，et al. Gonadotropin⁃
［25］ AZIM A A，COSTANTINI ⁃ FERRANDO M，OKTAY K. releasing hormone agonist combined with a levonorgestrel⁃
Safety of fertility preservation by ovarian stimulation with releasing intrauterine system or letrozole for fertility ⁃
letrozole and gonadotropins in patients with breast cancer： preserving treatment of endometrial carcinoma and com⁃
a prospective controlled study［J］. J Clin Oncol，2008，26 plex atypical hyperplasia in young women［J］. Int J Gynecol
（16）：2630-2635 Cancer，2017，27（6）：1178-1182
［26］RODGERS R J，REID G D，KOCH J，et al. The safety and ［37］ LOMBARDI FÄH V，DEL VENTO F，INTIDHAR LA⁃
efficacy of controlled ovarian hyperstimulation for fertility BIDI⁃GALY S，et al. Ovarian stimulation with letrozole in
preservation in women with early breast cancer：a system⁃ nulliparous young women with relapsing early⁃stage serous
atic review［J］. Hum Reprod，2017，32（5）：1033-1045 borderline ovarian tumors［J］. Gynecol Oncol Rep，2024，
［27］KIM J，TURAN V，OKTAY K. Long⁃term safety of letro⁃ 56：101531
zole and gonadotropin stimulation for fertility preservation ［38］BENVENUTI C，LAOT L，GRINDA T，et al. Is controlled
in women with breast cancer［J］. J Clin Endocrinol ovarian stimulation safe in patients with hormone receptor⁃
Metab，2016，101（4）：1364-1371 positive breast cancer receivingneoadjuvant chemothera⁃
［28］ROTHÉ F，LAMBERTINI M，GOLDRAT O，et al. Circu⁃ py?［J］. ESMO Open，2024，9（2）：102228
lating tumor DNA to interrogate the safety of letrozole⁃ ［39］ JAHANGIRI N，GHAFFARI F，HAFEZI M，et al. Ovarian
associated controlled ovarian stimulation for fertility reserve and stimulation response before chemotherapy
preservation in breast cancer patients［J］. Front Oncol， treatment in breast cancer patients undergoing fertility
2021，11：686625 preservation：a historical cohort study［J］. Ovarian Rese，
［29］CONCIN N，MATIAS⁃GUIU X，CIBULA D，et al. ESGO⁃ 2025，18（1）：222
ESTRO ⁃ ESP guidelines for the management of patients ［40］ SHAPIRA M，MEIROW D，RAVED D，et al. Controlled
with endometrial carcinoma：update2025［J］. The Lancet. ovarian stimulation for oocyte preservation in childhood
Oncology，2025，26（8）：423-435 cancer survivors who have undergone chemotherapy［J］.
［30］ CENTINI G，COLOMBI I，IANES I，et al. Fertility sparing Hum Reprod Open，2025，2025（2）：hoaf023
in endometrial cancer：where are we now?［J］. Cancers， ［41］ SONMEZER M，SACINTI K G，OKTAY K H. Female
2025，17（1）：112 fertility preservation：25 years of progress，expanding
［31］ LEONE ROBERTI MAGGIORE U，KHAMISY⁃FARAH indications and future prospects［J］. Hum Reprod Update，
R，BRAGAZZI N L，et al. Fertility⁃sparing treatment of 2025：dmaf026